Kymera Therapeutics, Inc. announced positive clinical results on June 2, 2025, from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The data surpassed Kymera’s target product profile, significantly de-risking the program and further validating its oral, biologics-like potential.
The study achieved over 90% mean STAT6 degradation in blood at all doses above 1.5 mg, and complete STAT6 degradation in both blood and skin at all multiple ascending dose (MAD) levels of 50 mg or greater. KT-621's impact on Th2 biomarkers, including median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%, was in line with or superior to published dupilumab results.
KT-621 was well-tolerated, with a safety profile undifferentiated from placebo, reporting no serious adverse events, no severe adverse events, and no treatment-related adverse events in more than one subject. This favorable safety profile was observed at MAD dose levels up to 200 mg, which is 16-fold above the dose level where 90% degradation in blood and skin was first achieved.
The company's KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients is actively recruiting, with data expected in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in the fourth quarter of 2025 and the first quarter of 2026, respectively, aiming to accelerate development and inform Phase 3 dose selection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.